Disclosure of Confidential Business Information under the Food and Drugs Act
Description of Program
The Disclosure of Confidential Business Information (CBI) under the Food and Drugs Act program involves determining whether CBI can be disclosed to requesters who carry out functions relating to the protection and promotion of human health or the safety of the public.
Why was a Privacy Impact Assessment (PIA) completed?
This PIA was completed as personal information is used to make an administrative decision as to whether CBI can be disclosed to an individual.
The PIA examines the privacy-related risks of the Disclosure of CBI under the Food and Drugs Act program and proposes methods to lower these risks.
This PIA focused on Health Canada’s collection, use, disclosure, and retention and disposition of personal information involved in the Program’s business processes.
The PIA recommended mitigation actions in the following risk areas: control and disclosure of records, sharing information within Health Canada, retention and disposition authorities, maintaining accuracy and the absence of a Personal Information Bank, which is currently being implemented.
If you would like more information about this Privacy Impact Assessment (PIA) please contact:
Health Canada / Public Health Agency of Canada Privacy Management Division (PMD)
Holland Cross - Tower B
1600 Scott Street, 4th Floor, Suite 410B
Postal Locator: 3107A
Ottawa, Ontario K1A 0K9
Teletypewriter: 1-800-465-7735 (Service Canada)
Report a problem or mistake on this page
- Date modified: